SML3453

MGCD0103

≥95% (HPLC)

• Synonym(e): MGCD, MGCD 0103, MGCD-0103, Mocetinostat, N-(2-Amino-phenyl)-4-((4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl)-benzamide
• Empirische Formel (Hill-System): C₂₃H₂₀N₆O
• CAS-Nummer: 726169-73-9
• Molekulargewicht: 396.44
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD10565970
• Assay: ≥95% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥95% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: N(Cc3ccc(cc3)C(=O)Nc4c(cccc4)N)c1nc(ccn1)c2cnccc2
• InChI: 1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
• InChI key: HRNLUBSXIHFDHP-UHFFFAOYSA-N

Beschreibung

Biochem/physiol Actions

MGCD0103 (Mocetinostat) is an orally active, potent and subtype-selective histone deacetylase (HDAC) inhibitor (IC50: class I HDAC1/2/3 = 0.15/0.29/1.66 μM, class IV HDAC11 = 0.59 μM, HDAC4/5/7/8 >10 μM) that effectively inhibits cellular HDAC activity (IC50 = 450 nM; Du145, HCT15, HCT116), resulting in an upregulated acetylation of histone H3 and H4, but not that of tubulin. MGCD0103 daily orally administration (60-120 mg/kg) is efficacious against A549 & H1437 tumor growth in mice in vivo.

Orally active, potent and HDAC1/2/3/11 subtype-selective histone deacetylase inhibitor with anti-tumor efficacy in mice in vivo.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable